Yayın:
Mechanism of actions of probiotics on type 2 diabetes: Development and complications

dc.contributor.authorAğagündüz, D.
dc.contributor.authorÇelik, E.
dc.contributor.authorCemali, Ö.
dc.contributor.authorYesildemir, O.
dc.contributor.authorDemirci, K.Ş.
dc.contributor.authorAkkus, G.
dc.contributor.authorEsatbeyoğlu, T.
dc.contributor.authorOzogul F.
dc.contributor.buuauthorYEŞİLDEMİR, ÖZGE
dc.contributor.departmentSağlık Bilimleri Fakültesi
dc.contributor.departmentBeslenme ve Diyetetik Ana Bilim Dalı
dc.contributor.scopusid57204096285
dc.date.accessioned2025-11-28T08:10:42Z
dc.date.issued2025-10-01
dc.description.abstractType 2 diabetes mellitus (T2DM) is a multifactorial metabolic disorder described by chronic hyperglycemia, insulin resistance, as well as low-grade inflammation. Recent research highlights the vital role of the gut microbiota in the pathogenesis and progression of T2DM. Dysbiosis can impair intestinal barrier integrity, promote systemic inflammation, and contribute to insulin resistance and glucose metabolism dysfunction. This review article investigates the mechanisms by which probiotics interact with gut microbiota and host signaling pathways to impact the onset and complications of T2DM. Databases were searched, and related articles were added, to get a thorough overview of the relationship between probiotics and T2DM and its complications. Probiotics have appeared as potential modulators of the gut microbiome, capable of restoring microbial balance and strengthening intestinal barrier function. Probiotics can influence glucose homeostasis through their multifaceted effects on the gut microbiota and host metabolism. Through the production of beneficial metabolites, suppress α-glucosidase activity, enhance short-chain fatty acid (SCFA) levels, competitive inhibition of pathogenic bacteria, regulation of gut-derived neurotransmitters such as serotonin, improve intestinal, and immune functions, probiotics may alleviate key mechanisms involved in T2DM development and its complications.
dc.identifier.doi10.1016/j.biopha.2025.118421
dc.identifier.issn0753-3322
dc.identifier.scopus2-s2.0-105012773217
dc.identifier.urihttps://hdl.handle.net/11452/56939
dc.identifier.volume191
dc.indexed.scopusScopus
dc.language.isoen
dc.publisherElsevier Masson s.r.l.
dc.relation.journalBiomedicine and Pharmacotherapy
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectType 2 diabetes
dc.subjectProbiotics
dc.subjectIntestinal barrier
dc.subjectGut microbiota
dc.subjectDysbiosis
dc.subjectDiabetic complications
dc.titleMechanism of actions of probiotics on type 2 diabetes: Development and complications
dc.typeReview
dspace.entity.typePublication
local.contributor.departmentSağlık Bilimleri Fakültesi/Beslenme ve Diyetetik Ana Bilim Dalı
local.indexed.atScopus
relation.isAuthorOfPublication2ea4b7ae-23a0-4e14-a804-4de1dc5dd616
relation.isAuthorOfPublication.latestForDiscovery2ea4b7ae-23a0-4e14-a804-4de1dc5dd616

Dosyalar

Orijinal seri

Şimdi gösteriliyor 1 - 1 / 1
Placeholder
Ad:
Yesildemir_vd_2025.pdf
Boyut:
3.79 MB
Format:
Adobe Portable Document Format